



Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference

November 9, 2021

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present and participate virtually at the 12th Annual Jefferies London Healthcare Conference.

Time and date: Virtual presentation available on-demand beginning on Thursday, November 18 at 8:00 a.m. GMT / 3:00 a.m. ET through Friday, November 19 at 5:00 p.m. GMT / 12:00 p.m. ET

Presenter: James Breitmeyer, M.D., Ph.D., President and CEO

Webcast Link: <https://wsw.com/webcast/jeff201/onct/1848600>

Links to the webcast and replay will be accessible on the Events & Presentations page of the Investors section on the Company's website at investor.oncternal.com.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising, yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes [zilovertamab](#) (formerly cirmtuzumab) an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1b/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, as well as a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL. Oncternal is also developing ONCT-808, a chimeric antigen receptor T cell ([CAR-T](#)) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The clinical pipeline also includes [ONCT-216](#) (formerly TK216), an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1/2 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. The early-stage pipeline also includes [ONCT-534](#) (formerly GTX-534), a dual-action androgen receptor inhibitor, that is in pre-clinical development as a potential treatment for castration resistant prostate cancer and other androgen-receptor dependent diseases. More information is available at <https://oncternal.com/>.

Investors

Richard Vincent
Chief Financial Officer
858-434-1113
rvincent@oncternal.com

Media

Corey Davis
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com



Source: Oncternal Therapeutics